Morgan Stanley
-
Hong Kong developer Pacific Century Premium Developments (PCPD) printed a $700m deal on Tuesday as part of its efforts to tender a 2022 bond.
-
UP Fintech Holding has launched a follow-on offering of new American depositary shares (ADS) worth around $173.5m.
-
Buyers piled into a debut sustainability-linked bond from Italian oil major Eni on Monday, despite there being some pushback from investors over higher polluting issuers coming to the ESG markets.
-
Piraeus is set to become the first Greek bank to print an additional tier one (AT1) bond — the next step in its capital plan after the closing of its €1.4bn equity raise last month.
-
Chinese online recruitment company Kanzhun has hit the road with an up to $912m Nasdaq listing.
-
Europe’s corporate bond market has seen an influx of ESG deals from highly polluting sectors, testing how much environmentally and socially conscious investors buy into firms' transition stories.
-
The French Community of Belgium (LCFB) sold its first social bond under its new social finance framework on Wednesday.
-
Bank borrowers were making good use of a narrow issuance window this week, drawing on the support of smaller sized but higher quality order books to command tight pricing in euros.
-
Unrated Portugeuse insurer Fidelidade resurrected its plans to print a tier two bond on Friday – almost three years after its first attempt at accessing the format.
-
Prospects for companies to issue more social bonds rose this week, with the debut issue by Electricité de France, a borrower with a long and influential track record in the green bond market.
-
Mamoura Diversified Global Holding sold a dual tranche dollar bond featuring a Formosa tranche on Thursday. Formosa bonds have been gaining traction among Middle East issuers as they seek to tap into Asian investor demand.
-
AstraZeneca, the UK drug company, showed the eager demand for merger and acquisition financings this week when it achieved ultra-tight pricing on a $7bn bond issue to fund its acquisition of US biotech firm Alexion Pharmaceuticals.